Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Digoxin
Drug ID BADD_D00668
Description Digoxin is one of the oldest cardiovascular medications used today.[A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure.[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.[L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
Indications and Usage Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients.[L9143] 2) To increase myocardial contraction in children diagnosed with heart failure.[L9143] 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.[L9143] In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.[L9143]
Marketing Status approved
ATC Code C01AA05
DrugBank ID DB00390
KEGG ID D00298
MeSH ID D004077
PubChem ID 2724385
TTD Drug ID D02OZE
NDC Product Code 82685-202; 42385-101; 69205-201; 57664-437; 59651-436; 70518-2959; 70954-202; 10135-748; 69205-101; 16714-590; 52584-410; 71610-019; 82685-201; 16714-591; 0115-9811; 0115-9822; 50090-5642; 57664-441; 63187-740; 69238-1992; 59212-240; 59651-438; 66689-327; 70515-261; 45085-0101; 69205-202; 0143-1240; 71335-1052; 0143-1241; 50090-5862; 60429-100; 0404-9850; 0054-0057; 69238-1991; 69292-605; 70515-263; 0641-1410; 51927-0291; 51655-403; 59212-242; 59212-249; 60429-099; 70518-3124; 70518-3421; 0615-8202; 0641-6184; 70954-201; 59695-0001; 59695-0002; 55154-5882; 59651-437; 60687-551; 71335-9610; 0904-5921; 51662-1217; 55154-5106; 60687-540; 70515-260; 70515-262; 70954-200; 0781-3059; 0904-5922; 10135-747; 55742-123; 59695-0004
UNII 73K4184T59
Synonyms Digoxin | Lanacordin | Lanicor | Lanoxicaps | Dilanacin | Digacin | Digitek | Digoregen | Digoxina Boehringer | Boehringer, Digoxina | Digoxine Nativelle | Nativelle, Digoxine | Hemigoxine Nativelle | Nativelle, Hemigoxine | Mapluxin | Lanoxin | Lanoxin-PG | Lanoxin PG | Lenoxin
Chemical Information
Molecular Formula C41H64O14
CAS Registry Number 20830-75-5
SMILES CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O) OC8)O)C)O)C)C)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Xanthopsia06.02.05.0020.000674%Not Available
Mental status changes19.07.01.0010.000211%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.007--Not Available
Hypoacusis04.02.01.0060.000105%
Retinal toxicity12.03.01.036; 06.09.03.0130.000211%Not Available
Sudden cardiac death02.03.04.016; 08.04.01.0080.000105%Not Available
General physical health deterioration08.01.03.0180.000632%Not Available
Tachyarrhythmia02.03.02.0080.000526%Not Available
Left ventricular dysfunction02.04.02.0110.000105%
Bradyarrhythmia02.03.02.0150.001126%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000316%Not Available
Dysstasia17.02.02.012; 15.03.05.011; 08.01.03.0890.000105%Not Available
Ventricular hypokinesia02.04.02.0130.000105%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000105%
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.000105%
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000158%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000105%Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.0110.000263%Not Available
Haemodynamic instability24.03.02.0060.000263%Not Available
Cardiac flutter02.03.02.0120.000211%Not Available
Electrocardiogram PR prolongation13.14.05.012--Not Available
Foetal death18.01.02.003; 08.04.01.0110.000263%
Pulseless electrical activity02.03.04.0200.000526%Not Available
Adverse event08.06.01.0100.000474%Not Available
Cardiac disorder02.11.01.0030.000421%Not Available
Electrocardiogram change13.14.05.014--Not Available
Ocular toxicity12.03.01.031; 06.11.01.0060.000105%Not Available
Ischaemia24.04.02.0040.000105%Not Available
Mental disorder19.07.01.002--Not Available
Poisoning12.03.01.004--Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene